Activation of the STING pathway in antigen-presenting cells has been proposed as a strategy to stimulate the adaptive immune response against tumours, but its clinical application is hampered by the instability, low specificity and low cytosolic entry of natural STING agonists. Here the authors present a platform for targeted ultrasound-mediated cytosolic delivery of STING agonists that shows efficacy in different animal tumour models and improves the response to checkpoint blockade therapies.
- Xuefeng Li
- Sina Khorsandi
- Jacques Lux
